Aprea Therapeutics moved to accelerate enrollment and broaden cohorts in its Phase 1 program for APR-1051, an oral WEE1 kinase inhibitor, after early clinical activity signals. The company plans to expand the dose-escalation trial site footprint from three to 10 and expects monthly enrollment to rise to six to 10 by the fourth quarter. Aprea is also expanding development into additional tumor types and combination arms, including uterine serous carcinoma and cyclin E–overexpressing platinum-resistant ovarian cancer, and plans to add arms for HPV-positive head and neck squamous cell carcinoma and colorectal cancer in combination regimens. The company’s stated goal is to de-risk future survival-focused development by sharpening which biomarker-defined populations show the strongest response and tolerability profile at progressing dose levels.